FDA Panel Recommends Pathogen-Agnostic Sequencing for Outbreak Detection
Pathogen-agnostic sequencing could serve as an early-warning detector for outbreaks, according to federal advisory recommendations.
- The FDA Microbiology Devices Panel supports pathogen-agnostic sequencing as a diagnostic tool for infectious disease emergencies.
- Experts warn that the untargeted method faces challenges with false results, validation standards, and high costs.
- State public health labs lack resources to validate every potential assay, leaving gaps during local disease surges.
Advisory Panel Backs Diagnostic Shift
An FDA advisory committee recommended establishing a framework for using pathogen-agnostic sequencing as a diagnostic tool during infectious disease outbreaks, Healio News reported on November 20, 2026. At a general issues meeting of the FDA’s Microbiology Devices Panel on Nov. 19, the panel said it believes pathogen-agnostic sequencing is becoming the standard in clinical laboratories.
“We think that during an outbreak, this kind of sequencing could have great value for early identification of an outbreak,” Robin Patel, acting chair of the Microbiology Devices Panel, said during the meeting. “We've evolved to a phase where this kind of testing is distributed now and is available in the field.” Robin Patel, acting chair of the Microbiology Devices Panel, said during the meeting.
Traditional molecular tests rely on a priori knowledge of a pathogen, creating blind spots when clinicians face unknown threats. Pathogen-agnostic sequencing analyzes genetic material in a patient specimen without first selecting a target, identifying sources more efficiently.
“This limitation that traditional molecular tests rely on a priori knowledge of the pathogen sets up an important question: What if we don’t know what we’re looking for?” Joseph Briggs, the deputy director of the FDA’s Division of Microbiology Devices, said in the FDA executive summary. Briggs said that untargeted genomic sequencing addresses that exact question.
Validation Hurdles and Economic Realities
Speakers cautioned that the technology is not perfect. Briggs warned that false positive or false negative results could delay responses during an emergency, alongside long turnaround times and complex results.
Validation also breaks traditional assumptions. John Barnes, the deputy director of the Office of Advanced Molecular Detection at the CDC, explained that pathogen-agnostic testing challenges existing frameworks built around targeted assays.
“Our validation paradigms are built around targeted assays and pathogen-agnostic testing really kind of breaks those foundational assumptions,” Barnes said in CDC presentation materials. Barnes noted it breaks assumptions like positive predictive value when a test can detect anything in a sample.
A study published in the Journal of Clinical Microbiology on September 10, 2026, demonstrated that a tiered classification model still misclassified approximately 1 in 40 cases. The research highlights the difficulty in determining whether a detected sequence represents a causative agent, a bystander, or a commensal organism.
Resource Limits in Public Health Labs
Cost remains a major barrier for public health laboratories with limited resources. Shirlee Wohl, project director at the New England Pathogen Genomics Center of Excellence, pointed to an enterovirus uptick in a Massachusetts hospital in September 2026.
Patients showed unusual neurological symptoms while scientists struggled to characterize the strain. Pathogen-agnostic sequencing could have helped, but state public health settings lacked the resources to maintain and validate specific assays for every possible enterovirus.
“There are many examples of scenarios where we in Massachusetts could have really used a validated pathogen-agnostic sequencing to make real public health impact and support outbreak response,” Wohl told Healio News.
Born in Winnipeg, Manitoba, Canada, Robin Patel moved to Montreal as a child and earned a BA in chemistry from Princeton University in 1985 before receiving her MD from McGill University in 1989. She joined the Mayo Clinic in 1996 and currently holds the Elizabeth P. and Robert E. Allen Professorship of Individualized Medicine while serving as Vice Chair of Education in the Department of Laboratory Medicine and Pathology and Director of the Infectious Diseases Research Laboratory.
Patel led the American Society for Microbiology as its 2019–2020 President and directed the Antibacterial Resistance Leadership Group Laboratory Center at the National Institutes of Health. In 2022, she became the second woman to receive the Hamao Umezawa Memorial Award from the International Society for Antimicrobial Chemotherapy.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.